Cannabis, HIV Infections, Neuropathic Pain
Conditions
Brief summary
This study will examine how medical cannabis use affects neuropathic pain, inflammation and adverse events in people living with HIV (PLWH) with neuropathic pain. We will study how varying ratios of THC and CBD in medical cannabis impact neuropathic pain, inflammation and adverse events.
Detailed description
This study will examine how medical cannabis use affects neuropathic pain in PLWH with neuropathic pain. We will enroll adults with HIV who have a) neuropathic pain, b) are actively certified for medical cannabis, and c) intend to have soft gel capsule products dispensed at Vireo (medical cannabis dispensary) (including a high THC:low CBD product, an equal THC:CBD product, and a low THC:high CBD product). Over 14 weeks, data sources will include questionnaires, blood samples, urine samples; medical, pharmacy, and Prescription Monitoring Program (PMP) records. The primary independent variable will be type of medical cannabis product dispensed at dispensary, and the primary outcome will be self-reported pain.
Interventions
None listed
Sponsors
National Institute on Drug Abuse (NIDA)
University of Colorado, Boulder
University of Pittsburgh
Vireo Health
Montefiore Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>= 18 years old * Diagnosis of HIV * Fluency in English * Active certification for medical cannabis * No medical cannabis dispensed or used within the previous 30 days * Intends to purchase soft-gel capsule medical cannabis at Vireo * ICD-10 diagnosis code for neuropathic pain, OR * Neuropathic pain in problem list of electronic medical record, OR * Neuropathic pain questionnaire-short form\>0
Exclusion criteria
* Inability to provide informed consent * Inability to complete 14 weeks of study visits * Medical cannabis use within 30 days prior to enrollment * Unique pain symptoms (e.g. multiple sclerosis, rheumatoid arthritis) * Terminal illness * Current or prior psychotic disorder * Street cannabis, opioid, cocaine, or benzodiazepine use in the past 30 days * Dispensed opioids of benzodiazepines within 60 days * Non-steroidal anti-inflammatory use within 7 days prior to enrollment * Steroid use within the past 14 days with duration of therapy \>=21 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain severity | 14 weeks | self-reported pain severity measured via the Brief Pain Interference (BPI) severity scale (1-10) with higher score indicating worse pain. Measured weekly with web- or phone-based questionnaire. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Circulating levels of inflammatory cytokines | 14 weeks | Tests levels of recent inflammation (panel of inflammatory markers) at two time points before starting medical cannabis and 14 weeks after starting medical cannabis. Reported in pg/mL |
| Antiretroviral adherence | 14 weeks | Measured at 0 and 14 weeks Visual Analog Scale \[VAS\] (0-100) with higher number indicating better adherence. |
| HIV Viral load suppression | 14 weeks | HIV viral load measured at two time points (baseline and 14 weeks; copies/mL) |
| Depression | 14 weeks | Measured at 0 and 14 weeks with the Patient Health Questionnaire- 9 \[PHQ-9\] (0-27) with higher score indicating worse depression |
| Anxiety | 14 weeks | Measured at 0 and 14 weeks with the Generalized Anxiety Disorder-7 \[GAD-7\] (0-21) with higher score indicating worse anxiety |
Outcome results
None listed